

ADMA BIOLOGICS, INC.  
Form 8-K  
June 10, 2016

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 7, 2016

ADMA BIOLOGICS, INC.  
(Exact name of registrant as specified in its charter)

|   |  |  |
|---|--|--|
| Delaware<br>(State or other jurisdiction<br>of incorporation) | 001-36728<br>(Commission<br>File Number) | 56-2590442<br>(IRS Employer<br>Identification No.) |
|---|--|--|

|  |                     |
|--|---------------------|
| 465 State Route 17, Ramsey, New Jersey<br>(Address of principal executive offices) | 07446<br>(Zip Code) |
|--|---------------------|

Registrant's telephone number, including area code: (201) 478-5552

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors and Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 7, 2016, the board of directors of ADMA Biologics, Inc. (the "Company") approved a 3% annual base salary increase, retroactive to January 1, 2016, for each of Adam Grossman, the Company's President and Chief Executive Officer; Brian Lenz, the Company's Vice President and Chief Financial Officer and Dr. James Mond, the Company's Executive Vice President, Chief Scientific Officer and Chief Medical Officer.

Item 5.07.Submission of Matters to a Vote of Security Holders.

At the annual meeting of stockholders (the "Annual Meeting") of the Company held on June 7, 2016, the holders of the Company's common stock voted to elect each of the following Class III directors to serve for a term of three years, until his successor is duly elected and qualified:

| Director            | Votes For | Votes Withheld | Broker Non-Votes |
|---------------------|-----------|----------------|------------------|
| Jerrold B. Grossman | 7,123,412 | 9,724          | 1,087,225        |
| Lawrence P. Guiheen | 7,076,102 | 57,034         | 1,087,225        |

At the Annual Meeting, the Company's stockholders also voted on the following proposal:

| Proposal  | For       | Against | Abstain |
|---|-----------|---------|---------|
| To ratify the appointment of CohnReznick LLP as the Company's independent registered public accounting firm for the year ending December 31, 2016 | 8,211,689 | 3,622   | 5,050   |

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

June 10, 2016

ADMA Biologics, Inc.

By: /s/ Brian Lenz  
Name: Brian Lenz  
Title: Chief Financial Officer